[Pharmaceutical development and clinical experiment of new antidiabetic drugs, premixed preparations of insulin lispro (Humalog Mix 25 and Humalog Mix 50) and intermediate-acting insulin lispro (Humalog N)].
Awa
Takao
T
awa_takao@lilly.com
Nakata
Tetsushi
T
Shigeta
Hirofumi
H
D061265:Biphasic Insulins; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D061268:Insulin Lispro; D007336:Insulin, Isophane; D011788:Quality of Life
D061265:Biphasic Insulins; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; C482266:insulin lispro, isophane insulin lispro drug combination (25:75); C557537:isophane insulin, insulin lispro drug combination 50:50; D007336:Insulin, Isophane